Drug Profile

Indigotindisulfonate sodium - Provepharm

Alternative Names: Bludigo; Indigotindisulfonate sodium injection - Provepharm

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Provepharm
Developer Provepharm; Sagent Pharmaceuticals
Class Diagnostic agents; Indoles; Small molecules
Mechanism of Action Diagnostic imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Kidney disorders

Most Recent Events

03 Dec 2025 Provepharm and Sagent Pharmaceuticals agree to co-promote indigotindisulfonate sodium in USA for Kidney disorders
03 Dec 2025 Launched for Kidney disorders (Diagnosis) in USA (IV)
07 Jun 2024 Prove Pharm plans a phase III trial for Kidney disorders (Diagnosis, In children, In adoescents, In infants) in June 2024 (NCT06448143)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com